These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 7574783

  • 1. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin].
    Matsuoka H, Yano K, Baba H, Kounoe S, Seo Y, Saito T, Tomoda H, Wakasugi H.
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1644-6. PubMed ID: 7574783
    [Abstract] [Full Text] [Related]

  • 2. Potential advantages in therapeutic index of OK-432 ointment to abdominal skin over systemic applied in a mouse model.
    Matsuoka H, Yano K, Wasasugi H, Seo Y, Saito T, Tomoda H.
    Cancer Lett; 1996 Mar 19; 101(1):15-20. PubMed ID: 8625276
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H, Oku N, Moriya Y, Kusumoto S, Suda Y.
    Int Immunopharmacol; 2008 Jan 19; 8(1):12-9. PubMed ID: 18068095
    [Abstract] [Full Text] [Related]

  • 4. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state.
    Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O'Donnell MA.
    J Immunol; 1997 Jun 15; 158(12):5619-26. PubMed ID: 9190909
    [Abstract] [Full Text] [Related]

  • 5. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N.
    J Med; 1998 Jun 15; 29(3-4):199-215. PubMed ID: 9865458
    [Abstract] [Full Text] [Related]

  • 6. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432].
    Mizushima Y, Hirata H, Sakamoto K, Sato M, Morikage T, Maruyama M, Sasaki K, Yano S.
    Gan To Kagaku Ryoho; 1987 Sep 15; 14(9):2710-5. PubMed ID: 3631971
    [Abstract] [Full Text] [Related]

  • 7. [Combined effects of cis-DDP and OK-432 on ascitic mastocytoma in mice: optimal period for the administration of OK-432].
    Komatsu K, Nakamura W.
    C R Seances Soc Biol Fil; 1986 Sep 15; 180(1):117-20. PubMed ID: 2943364
    [Abstract] [Full Text] [Related]

  • 8. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K, Toge T.
    Int J Oncol; 2004 Apr 15; 24(4):959-66. PubMed ID: 15010836
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic effects of streptococcal preparation OK-432 on atopic dermatitis-like lesions in NC/Nga mice: possible shift from a Th2- to Th1-predominance.
    Horiuchi Y, Bae S, Katayama I, Nishioka K.
    J Dermatol Sci; 2004 Sep 15; 35(3):187-97. PubMed ID: 15381240
    [Abstract] [Full Text] [Related]

  • 10. [Production of a cytotoxic factor in mouse peritoneal fluid by OK-432, a streptococcal preparation].
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I.
    Gan To Kagaku Ryoho; 1986 May 15; 13(5):1905-10. PubMed ID: 3707150
    [Abstract] [Full Text] [Related]

  • 11. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T, Okamoto M, Ohe G, Furuichi S, Nishikawa H, Uddin Ahmed S, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2003 May 15; 3(5):643-55. PubMed ID: 12757734
    [Abstract] [Full Text] [Related]

  • 12. Control of endotoxin shock by the dried preparation of low virulent Streptococcus pyogenes OK-432.
    Nose M, Uzawa A, Nomura M, Ikarashi Y, Nakata Y, Akashi M, Suzuki G.
    Cell Immunol; 1998 Sep 15; 188(2):97-104. PubMed ID: 9756639
    [Abstract] [Full Text] [Related]

  • 13. Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Uddin Ahmed S, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Sato M.
    Int Immunopharmacol; 2006 May 15; 6(5):764-73. PubMed ID: 16546707
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
    Homma S, Sagawa Y, Komita H, Koido S, Nagasaki E, Ryoma Y, Okamoto M.
    Cancer Immunol Immunother; 2007 Aug 15; 56(8):1265-74. PubMed ID: 17219148
    [Abstract] [Full Text] [Related]

  • 15. [Antitumor effect of intraperitoneal administration of a streptococcal preparation, OK-432, in carcinomatous peritonitis. I. Experimental study in the rat].
    Saji S, Miya K, Oshita H, Nonomura O, Yokoyama Y, Yamamoto S, Takekoshi T, Sakata K.
    Gan To Kagaku Ryoho; 1982 Nov 15; 9(11):1961-8. PubMed ID: 7184383
    [Abstract] [Full Text] [Related]

  • 16. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.
    Cancer Res; 2004 Aug 01; 64(15):5461-70. PubMed ID: 15289356
    [Abstract] [Full Text] [Related]

  • 17. [Induction of mouse peritoneal cytotoxic factor by OK-432. (3). Comparison between LPS and OK-432 as eliciting agents].
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Nishii Y, Suzuki S, Watanabe N, Niitsu Y, Urushizaki I.
    Gan To Kagaku Ryoho; 1986 Jul 01; 13(7):2419-24. PubMed ID: 3729496
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of orally administered streptococcal preparation, OK-432 on murine solid tumors and its absorption from the gut.
    Nio Y, Shiraishi T, Tsuchitani T, Tobe T, Sugawara Y, Saito M, Kamiyama H.
    In Vivo; 1989 Jul 01; 3(5):307-13. PubMed ID: 2519870
    [Abstract] [Full Text] [Related]

  • 19. Topical streptococcal preparation, OK-432, for atopic dermatitis.
    Horiuchi Y.
    J Dermatolog Treat; 2005 Apr 01; 16(2):117-20. PubMed ID: 16019627
    [Abstract] [Full Text] [Related]

  • 20. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T, Okamoto M, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Akira S, Sato M.
    J Immunother; 2006 Apr 01; 29(2):143-50. PubMed ID: 16531815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.